This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Nadvi, S. Z. Articles by Ravindranath, Y. Search for Related Content PubMed PubMed Citation Articles by Nadvi, S. Z. Articles by Ravindranath, Y. Social Bookmarking                         What's this?

Low Frequency of Meperidine-Associated Seizures in Sickle Cell Disease

Sharada Sarnaik, MBBS

Yaddanapudi Ravindranath, MBBS

Department of Pediatrics, Wayne State University School of Medicine, and Division of Hematology/Oncology, Children's Hospital of Michigan, Detroit, MI

Pain control measures in sickle cell diseases are not uniform. Most clinicians use parenteral morphine or meperidine for severe pain. Reports of seizures associated with meperidine have led to a growing reliance on intravenous morphine, usually with patient-controlled devices. Acceptance of morphine has been poor among patients, and many prefer meperidine. The aim of this retrospective study was to determine the incidence of meperidine-associated seizures in a large, mostly pediatric population with sickling disorders. The results suggest that the incidence of seizures with meperidine is extremely small (0.4% of patients; 0.06% of admissions). The risk of seizures should not dissuade clinicians from using this drug.

Clinical Pediatrics, Vol. 38, No. 8, 459-462 (1999)
DOI: 10.1177/000992289903800803


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?